DiaVacs Announces Licensing Agreement with University of Pittsburgh for Novel Dendritic Cell and Microsphere Delivery Technologies for Treatment of Type 1 Diabetes

April 29, 2014 DiaVacs today announces that it has entered into a licensing agreement with the¬†University of Pittsburgh¬†for intellectual property pertaining to novel dendritic cell and antisense oligonucleotide microsphere delivery technologies for the treatment of type 1 diabetes. DiaVacs plans to apply this innovative technology to the development of a microsphere formulation of an antisense-nucleotide vaccine. According to initial studies …